Sarah-Jane James, imaging market analyst for Signify Research, discusses key trends in the specialty that she saw at the Radiological Society of North America's annual meeting.
Florida-based Cardiovascular Associates of America, one of the largest private equity-backed cardiology management groups in the United States, just got a little bigger.
AccurECG 2.0 was designed to interpret a total of 13 different rhythm classifications, including atrial fibrillation, atrial flutter and ventricular tachycardia.
Ultrasight's AI guidance technology for echo exams, showing a bar graph for image quality and an illustration of where the probe needs to be positioned on the anatomy.
This update helps health systems get more value out of UltraSight's advanced AI technology—all without buying brand new ultrasound equipment.
Image courtesy of the Independent Medical Alliance.
A veteran cardiologist is back on the job after reportedly being fired for his participation in a controversial CDC panel. His wife shared the update, saying they were "truly humbled" by everyone who came to his defense.
Based on feedback from the FDA, Aspire Biopharma plans on completing a multicenter clinical trial and then seeking regulatory approval for its new high-dose sublingual aspirin therapy.
ASE President David Wiener, MD, discussed his goals for 2026 in a new video interview. "The imager who doesn't use artificial intelligence will be replaced by the imager who does,” he said.
Early evidence suggests CBD could help clinicians treat pericarditis, myocarditis and other significant heart conditions. Additional research is still required, however, including many more clinical trials.
This news follows similar announcements from Humana, Cigna and UnitedHealthcare; a majority of insured Americans can now be treated with these technologies and have the procedure covered by their provider.
